June 21, 2025 10:53 AM EDTUpdated 01:15 PM
R&D

A puz­zling up­date from No­vo Nordisk and new da­ta from Roche at #ADA25

Elizabeth Cairns

Senior biopharma journalist

The an­nu­al meet­ing of the Amer­i­can Di­a­betes As­so­ci­a­tion is un­der­way in Chica­go. The con­fab has al­ready yield­ed a ma­jor up­date from Ver­tex …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

FDA's top cell and gene ther­a­py lead­ers ex­it agency in on­go­ing CBER changes

In­side the FDA’s ‘lis­ten­ing’ tour: Of­fi­cials agree US lags be­hind Chi­na on drug de­vel­op­ment

Ver­tex's di­a­betes cell ther­a­py al­lows 10 pa­tients to come off in­sulin

Af­ter a qui­et year, Xaira un­wraps some of its AI re­search, eye­ing a vir­tu­al cell

Phar­ma com­pa­nies are weigh­ing how a drug’s IP lo­ca­tion could im­pact tar­iffs

sponsored

This com­pa­ny has spent a decade in­no­vat­ing NGS-based com­pan­ion di­ag­nos­tics world­wide–what’s next?

A service from the Financial Times